Asensus Surgical Inc Stock Price, News & Analysis

Asensus Surgical (NYSE American: ASXC) announced the installation of a second Senhance Surgical System at Kitakyushu General Hospital in Japan, marking a significant expansion of its surgical offerings. Kitakyushu has successfully utilized its first system since January 2020, completing over 300 procedures. The addition of this second system highlights the clinical value and versatility of the Senhance platform, which incorporates augmented intelligence and advanced features like haptic feedback and the Intelligent Surgical Unit. This development is expected to enhance patient outcomes and further solidify Asensus's position in the digital surgery market.

Asensus Surgical (NYSE American: ASXC) has signed an agreement with Kashiwa Kosei General Hospital in Japan to lease the Senhance® Surgical System. This partnership is part of Asensus's expansion in a rapidly growing market. The Senhance system, known for its digital laparoscopic capabilities and use of augmented intelligence, aims to enhance surgical performance and patient outcomes. With a new thoracic indication approved, the hospital's surgery department is set to benefit from advanced technology, improving patient care and surgical effectiveness.

Asensus Surgical, Inc. (ASXC) announces that GPR Gesundheits- und Pflegezentrum Klinikum in Rüsselsheim, Germany, will lease its Senhance Surgical System. This marks the 10th hospital in Germany to adopt this technology, known for enhancing surgical performance through augmented intelligence and machine learning. The system is designed for high-volume procedures in specialties such as gynecology and urology. The partnership highlights increasing traction in Germany, Europe's largest robotics market, which could positively influence surgical demand and outcomes.

Asensus Surgical, Inc. (ASXC) has announced the sale of a Senhance Surgical System to a distribution partner in Germany. This system will be installed at an oncology-focused hospital, showcasing an increasing demand for the technology in Eastern Europe and the CIS region. The CEO, Anthony Fernando, expressed enthusiasm over the hospital's financial commitment to the Senhance System, emphasizing its clinical relevance and potential to improve surgical outcomes. The Senhance System is designed to enhance surgical precision and efficiency through augmented intelligence and machine learning.

Asensus Surgical, Inc. (NYSE American: ASXC) announced that CFO Shameze Rampertab will participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference in Miami on December 8, 2022. The company will present a panel discussion on early commercial MedTech technologies at 11:00 AM ET, followed by a Key Opinion Leader Luncheon at 12:15 PM ET, featuring Dr. Steven McCarus. Asensus is focused on enhancing surgical outcomes through Performance-Guided Surgery™ and the Senhance® Surgical System, which is currently available in multiple regions.

Asensus Surgical, Inc. (ASXC) reported its third quarter 2022 results, maintaining revenue at $2.6 million year-over-year, driven by over 1,900 procedures performed, a 27% increase from 2021. The company initiated five new Senhance programs and submitted a 510(k) application for pediatric use in the U.S. Operating expenses rose to $17.2 million, leading to a net loss of $18.9 million or $0.08 per share. The firm held $88.3 million in cash and investments as of September 30, 2022, and anticipates initiating 8-10 new Senhance systems in 2022.

Asensus Surgical (ASXC) has announced that Dr. von Hauner Children’s Hospital in Munich, Germany, has signed an agreement to lease the Senhance Surgical System, marking the first dedicated pediatric use of the system. This represents a significant milestone as the 9th hospital in Germany to adopt the Senhance technology, aimed at improving pediatric surgical outcomes through minimally invasive techniques. The system's advanced features, including 3mm instruments and haptic feedback, are expected to enhance the surgical experience for pediatric surgeons and their patients.

Asensus Surgical, Inc. (NYSE American: ASXC) announced plans to release its third-quarter financial and operational results for 2022 after market hours on November 10, 2022. A conference call will occur at 4:30 p.m. ET on the same day to discuss these results, with a simultaneous webcast available. Asensus focuses on transforming surgical practices through its Senhance Surgical System, aiming for superior outcomes in Performance-Guided Surgery. Their technology integrates machine vision and deep learning to address current shortcomings in surgical procedures.

Asensus Surgical, Inc. (ASXC) announced a leasing agreement for its Senhance Surgical System with the St. Bernhard Hospital in Germany. This advanced robotic platform focuses on minimally invasive surgery and is equipped with augmented intelligence to enhance surgical performance and patient outcomes. The system features unique capabilities like haptic feedback and 3D visualization, making it a pioneering addition to the clinic's surgical offerings. The partnership aims to improve surgical precision and reduce variability.